Labopharm (DDSS) Drug being delayed by FDA review. Stock down by more than half to 52-week low of $2.83 from 52-week high of $9.07.

Point Therapeutics (POTP) After putting drug trial on hold, cuts 60% of workforce. Drops to $.10 from 52-week high of $3.01.

Spatialight (HDTV) Maker of liquid crystal microdisplays used in high-definition keeps falling after poor quarterly results. Down to $.10 from 52-week high of $3.10.

Headwaters (HW) Provides products to energy and construction industries. Debate over coal-to-fuel programs, including companies that HW supplies hurt stock price. Down to $19.10 from 52-week high of $27.81.

Douglas A. McIntyre